List view / Grid view
The British Generic Manufacturers Association (BGMA) represents the interests of UK-based manufacturers and suppliers of generic and biosimilar medicines and promotes the development and understanding of the generic and biosimilar medicines industry in the United Kingdom.
Mark Samuels, Chief Executive of the British Generic Manufacturers Association (BGMA), urges EU and UK to put patients above politics in solving medicine supply challenges for Northern Ireland.
The DHSC has confirmed that several pharmaceutical industry bodies have agreed to NDAs regarding plans for a no-deal Brexit.
The associations representing the European and British life science industry have launched a joint policy document on the potential impact of the United Kingdom’s exit from the European Union...
The EMA will relocate to Amsterdam in the Netherlands. The Agency now has just over 16 months to prepare for the move and take up its operations in Amsterdam on 30 March 2019 at the latest...
The British Generic Manufacturers Association (BGMA) will stage the next meeting of its Quality Forum – in conjunction with the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) - on Wednesday, July 8th.
25 February 2015 | By British Generic Manufacturers Association
The onset of biosimilar competition in the UK in Infliximab is another significant milestone in the development of the sector in this country according to the British Generic Manufacturers Association (BGMA).
Warwick Smith, Director General of the BGMA, has welcomed the DofH's decision not to introduce an additional price cut for branded generic medicines...
The British Generic Manufacturers Association will stage the next meeting of its Quality Forum – in conjunction with the MHRA - on Tuesday, February 24th...
13 November 2014 | By British Generic Manufacturers Association
Price cuts for branded generic medicines as part of proposed Government changes to the statutory scheme to control the prices of branded health service medicines will undermine innovation, create uncertainty, reduce competition and ultimately undermine patient benefits...
Response from the British Generic Manufacturers Association (BGMA) to a new report issued today by the Academy of Medical Royal Colleges...
Auditing will be a key theme of the British Generic Manufacturers Association’s (BGMA) next BGMA Quality Forum meeting on Wednesday, November 12th which is run in partnership with the MHRA.
The British Generic Manufacturers Association (BGMA) has appointed Thomas Broeer, managing director of Kent Pharmaceuticals, as its new chair for the next two years.
BGMA welcomes EU General Court ruling that AstraZeneca abused its dominant position by preventing the marketing of generic omeprazole.
26 May 2010 | By College Hill
Michael Cann, Director Generics at Actavis, took over as Chairman of the BGMA at the Association’s AGM in London on 26 May. He replaces Kim Innes of Teva, who will serve as Vice Chair for a year.
